{"id":"NCT00976937","sponsor":"Sanofi","briefTitle":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","officialTitle":"A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-09-15","resultsPosted":"2016-10-11","lastUpdate":"2016-10-11"},"enrollment":319,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DRUG","name":"Lixisenatide Placebo","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClik®"]},{"type":"DRUG","name":"Sitagliptin","otherNames":["Januvia®"]},{"type":"DRUG","name":"Sitagliptin Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Sitagliptin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index \\[BMI\\] greater than or equal to 30 kilogram per square meter \\[kg/m\\^2\\]) type 2 diabetic patients less than 50 years of age, over a period of 24 weeks of treatment.\n\nThe primary objective of this study is to assess the efficacy of lixisenatide, in comparison to sitagliptin, as an add-on treatment to metformin on a composite endpoint of glycemic control in terms of glycosylated hemoglobin (HbA1c) and body weight, at Week 24.\n\nSecondary objectives are to assess the effects of lixisenatide, in comparison to sitagliptin, as an add-on treatment to metformin on absolute changes in HbA1c values and body weight; fasting plasma glucose (FPG); plasma glucose, insulin, C-peptide, glucagon, and proinsulin during a 2-hour standardized meal test; insulin resistance assessed by homeostatic model assessment of insulin resistance (HOMA-IR); beta cell function assessed by homeostatic model assessment of beta-cell function (HOMA-beta); to evaluate safety, tolerability, and anti-lixisenatide antibody development.","primaryOutcome":{"measure":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Lixisenatide","deltaMin":12,"sd":null},{"arm":"Sitagliptin","deltaMin":7.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1696"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":24},"locations":{"siteCount":92,"countries":["United States","Australia","Brazil","Canada","Chile","Germany","Guatemala","Mexico","Peru","Poland","Romania","Russia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":158},"commonTop":["Nausea","Headache","Diarrhoea","Nasopharyngitis","Influenza"]}}